Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis
Objectives. To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA. Methods. A systematic review of the literature and meta-analysis were performed. We included ra...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2012-01, Vol.51 (1), p.60-68 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 1 |
| container_start_page | 60 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 51 |
| creator | Chauffier, Karine Salliot, Carine Berenbaum, Francis Sellam, Jérémie |
| description | Objectives. To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA.
Methods. A systematic review of the literature and meta-analysis were performed. We included randomized controlled trials (RCTs) assessing the effect of biotherapies vs placebo on fatigue, in combination with DMARDs. Fatigue was measured using the functional assessment of chronic illness therapy-fatigue (FACIT-F) or short-form 36 (SF-36) vitality scores at baseline and at Week 24. The results were in effect size (ES) for each biotherapy (or class of biotherapy) vs placebo. An ES of 0.8 as important.
Results. From the 763 published studies, 10 RCTs were included in the analysis: seven involved IR-DMARD RA and three IR-anti-TNF. Among the 3837 included patients with established RA, 1227 patients were treated with an anti-TNF, 420 with rituximab, 258 with abatacept, 205 with tocilizumab and 1727 received placebo. The overall ESs of all biotherapies vs placebo on fatigue were small (ES = 0.45; 95% CI 0.31, 0.58) as well as for anti-TNFs (ES = 0.36; 95% CI 0.21, 0.51). The ESs were small in IR-DMARD RA (ES = 0.38; 95% CI 0.30, 0.46), similar between anti-TNF and non-anti-TNF agents and moderate in IR-anti-TNF RA (ES = 0.57; 95% CI 0.27, 0.86).
Conclusion. Few studies reported the impact of biotherapies on fatigue. The effect of biotherapies on fatigue in RA is small. |
| doi_str_mv | 10.1093/rheumatology/ker162 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_912638695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/ker162</oup_id><sourcerecordid>912638695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-1bf5e530620bd66e7c0485ffb1ac229ef7238ddec7143bacc6f949f6fd0fbfc33</originalsourceid><addsrcrecordid>eNqNkMtKxDAUhoMo3p9AkGzEVTWXJtO6k2G8gOBG1-U0PXGibTMmqTJvb4cZL0tX58D5_u_AT8gJZxeclfIyzHHoIPnWvywv3zBwLbbIPs-1yJiUYvtnF_keOYjxlTGmuCx2yZ7giistyn0SZtaiSdRbWjuf5hhg4TBS31MLyb0MSF1Pv1-5hkJI8-CSi1cUaFzGhOPBGRrww-HnyjNKaOvSaEpDQAp9QztMkEEP7TK6eER2LLQRjzfzkDzfzJ6md9nD4-399PohMzkvUsZrq1BJpgWrG61xYlheKGtrDkaIEu1EyKJp0Ex4LmswRtsyL622DbO1NVIekvO1dxH8-4AxVZ2LBtsWevRDrEoutCx0qUZSrkkTfIwBbbUIroOwrDirVl1Xf7uu1l2PqdONf6g7bH4y3-WOwNkGgGigtQF64-Ivp5TWRcFG7mLN-WHxr89feaugAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>912638695</pqid></control><display><type>article</type><title>Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Chauffier, Karine ; Salliot, Carine ; Berenbaum, Francis ; Sellam, Jérémie</creator><creatorcontrib>Chauffier, Karine ; Salliot, Carine ; Berenbaum, Francis ; Sellam, Jérémie</creatorcontrib><description>Objectives. To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA.
Methods. A systematic review of the literature and meta-analysis were performed. We included randomized controlled trials (RCTs) assessing the effect of biotherapies vs placebo on fatigue, in combination with DMARDs. Fatigue was measured using the functional assessment of chronic illness therapy-fatigue (FACIT-F) or short-form 36 (SF-36) vitality scores at baseline and at Week 24. The results were in effect size (ES) for each biotherapy (or class of biotherapy) vs placebo. An ES of <0.5 was considered as small, between 0.5 and 0.8 as moderate and >0.8 as important.
Results. From the 763 published studies, 10 RCTs were included in the analysis: seven involved IR-DMARD RA and three IR-anti-TNF. Among the 3837 included patients with established RA, 1227 patients were treated with an anti-TNF, 420 with rituximab, 258 with abatacept, 205 with tocilizumab and 1727 received placebo. The overall ESs of all biotherapies vs placebo on fatigue were small (ES = 0.45; 95% CI 0.31, 0.58) as well as for anti-TNFs (ES = 0.36; 95% CI 0.21, 0.51). The ESs were small in IR-DMARD RA (ES = 0.38; 95% CI 0.30, 0.46), similar between anti-TNF and non-anti-TNF agents and moderate in IR-anti-TNF RA (ES = 0.57; 95% CI 0.27, 0.86).
Conclusion. Few studies reported the impact of biotherapies on fatigue. The effect of biotherapies on fatigue in RA is small.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/ker162</identifier><identifier>PMID: 21515629</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; Biological Products - therapeutic use ; Diseases of the osteoarticular system ; Drug Therapy, Combination ; Fatigue - drug therapy ; Fatigue - etiology ; Humans ; Inflammatory joint diseases ; Medical sciences ; Severity of Illness Index ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Rheumatology (Oxford, England), 2012-01, Vol.51 (1), p.60-68</ispartof><rights>The Author 2011. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-1bf5e530620bd66e7c0485ffb1ac229ef7238ddec7143bacc6f949f6fd0fbfc33</citedby><cites>FETCH-LOGICAL-c418t-1bf5e530620bd66e7c0485ffb1ac229ef7238ddec7143bacc6f949f6fd0fbfc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,1586,4028,27932,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25566880$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21515629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chauffier, Karine</creatorcontrib><creatorcontrib>Salliot, Carine</creatorcontrib><creatorcontrib>Berenbaum, Francis</creatorcontrib><creatorcontrib>Sellam, Jérémie</creatorcontrib><title>Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Objectives. To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA.
Methods. A systematic review of the literature and meta-analysis were performed. We included randomized controlled trials (RCTs) assessing the effect of biotherapies vs placebo on fatigue, in combination with DMARDs. Fatigue was measured using the functional assessment of chronic illness therapy-fatigue (FACIT-F) or short-form 36 (SF-36) vitality scores at baseline and at Week 24. The results were in effect size (ES) for each biotherapy (or class of biotherapy) vs placebo. An ES of <0.5 was considered as small, between 0.5 and 0.8 as moderate and >0.8 as important.
Results. From the 763 published studies, 10 RCTs were included in the analysis: seven involved IR-DMARD RA and three IR-anti-TNF. Among the 3837 included patients with established RA, 1227 patients were treated with an anti-TNF, 420 with rituximab, 258 with abatacept, 205 with tocilizumab and 1727 received placebo. The overall ESs of all biotherapies vs placebo on fatigue were small (ES = 0.45; 95% CI 0.31, 0.58) as well as for anti-TNFs (ES = 0.36; 95% CI 0.21, 0.51). The ESs were small in IR-DMARD RA (ES = 0.38; 95% CI 0.30, 0.46), similar between anti-TNF and non-anti-TNF agents and moderate in IR-anti-TNF RA (ES = 0.57; 95% CI 0.27, 0.86).
Conclusion. Few studies reported the impact of biotherapies on fatigue. The effect of biotherapies on fatigue in RA is small.</description><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Biological Products - therapeutic use</subject><subject>Diseases of the osteoarticular system</subject><subject>Drug Therapy, Combination</subject><subject>Fatigue - drug therapy</subject><subject>Fatigue - etiology</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Medical sciences</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtKxDAUhoMo3p9AkGzEVTWXJtO6k2G8gOBG1-U0PXGibTMmqTJvb4cZL0tX58D5_u_AT8gJZxeclfIyzHHoIPnWvywv3zBwLbbIPs-1yJiUYvtnF_keOYjxlTGmuCx2yZ7giistyn0SZtaiSdRbWjuf5hhg4TBS31MLyb0MSF1Pv1-5hkJI8-CSi1cUaFzGhOPBGRrww-HnyjNKaOvSaEpDQAp9QztMkEEP7TK6eER2LLQRjzfzkDzfzJ6md9nD4-399PohMzkvUsZrq1BJpgWrG61xYlheKGtrDkaIEu1EyKJp0Ex4LmswRtsyL622DbO1NVIekvO1dxH8-4AxVZ2LBtsWevRDrEoutCx0qUZSrkkTfIwBbbUIroOwrDirVl1Xf7uu1l2PqdONf6g7bH4y3-WOwNkGgGigtQF64-Ivp5TWRcFG7mLN-WHxr89feaugAA</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Chauffier, Karine</creator><creator>Salliot, Carine</creator><creator>Berenbaum, Francis</creator><creator>Sellam, Jérémie</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201201</creationdate><title>Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis</title><author>Chauffier, Karine ; Salliot, Carine ; Berenbaum, Francis ; Sellam, Jérémie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-1bf5e530620bd66e7c0485ffb1ac229ef7238ddec7143bacc6f949f6fd0fbfc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Biological Products - therapeutic use</topic><topic>Diseases of the osteoarticular system</topic><topic>Drug Therapy, Combination</topic><topic>Fatigue - drug therapy</topic><topic>Fatigue - etiology</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Medical sciences</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chauffier, Karine</creatorcontrib><creatorcontrib>Salliot, Carine</creatorcontrib><creatorcontrib>Berenbaum, Francis</creatorcontrib><creatorcontrib>Sellam, Jérémie</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chauffier, Karine</au><au>Salliot, Carine</au><au>Berenbaum, Francis</au><au>Sellam, Jérémie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2012-01</date><risdate>2012</risdate><volume>51</volume><issue>1</issue><spage>60</spage><epage>68</epage><pages>60-68</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Objectives. To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA.
Methods. A systematic review of the literature and meta-analysis were performed. We included randomized controlled trials (RCTs) assessing the effect of biotherapies vs placebo on fatigue, in combination with DMARDs. Fatigue was measured using the functional assessment of chronic illness therapy-fatigue (FACIT-F) or short-form 36 (SF-36) vitality scores at baseline and at Week 24. The results were in effect size (ES) for each biotherapy (or class of biotherapy) vs placebo. An ES of <0.5 was considered as small, between 0.5 and 0.8 as moderate and >0.8 as important.
Results. From the 763 published studies, 10 RCTs were included in the analysis: seven involved IR-DMARD RA and three IR-anti-TNF. Among the 3837 included patients with established RA, 1227 patients were treated with an anti-TNF, 420 with rituximab, 258 with abatacept, 205 with tocilizumab and 1727 received placebo. The overall ESs of all biotherapies vs placebo on fatigue were small (ES = 0.45; 95% CI 0.31, 0.58) as well as for anti-TNFs (ES = 0.36; 95% CI 0.21, 0.51). The ESs were small in IR-DMARD RA (ES = 0.38; 95% CI 0.30, 0.46), similar between anti-TNF and non-anti-TNF agents and moderate in IR-anti-TNF RA (ES = 0.57; 95% CI 0.27, 0.86).
Conclusion. Few studies reported the impact of biotherapies on fatigue. The effect of biotherapies on fatigue in RA is small.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21515629</pmid><doi>10.1093/rheumatology/ker162</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2012-01, Vol.51 (1), p.60-68 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_912638695 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Biological and medical sciences Biological Products - therapeutic use Diseases of the osteoarticular system Drug Therapy, Combination Fatigue - drug therapy Fatigue - etiology Humans Inflammatory joint diseases Medical sciences Severity of Illness Index Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T02%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20biotherapies%20on%20fatigue%20in%20rheumatoid%20arthritis:%20a%20systematic%20review%20of%20the%20literature%20and%20meta-analysis&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Chauffier,%20Karine&rft.date=2012-01&rft.volume=51&rft.issue=1&rft.spage=60&rft.epage=68&rft.pages=60-68&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/ker162&rft_dat=%3Cproquest_cross%3E912638695%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=912638695&rft_id=info:pmid/21515629&rft_oup_id=10.1093/rheumatology/ker162&rfr_iscdi=true |